ArticleFrontiers in veterinary science2026
Pharmacokinetics of HDM7006, a high-potency balanced GLP-1/GIP dual agonist, in healthy domestic cats.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HDM7006 is a GLP-1R/GIPR dual agonist developed for body weight management in obese or overweight cats. Objective: To Investigate the pharmacokinetic (PK) characteristics of HDM7006 in cats. Animals: Forty-eight healthy adult cats were enrolled. Methods: In the single-dose PK study, 40 cats were divided into five groups receiving 0.1, 0.5, 1.0 or 2.0 mg/kg (SC) or 1.0 mg/kg (intravenous, IV) of HDM7006, respectively. In the multiple-dose PK study, 8 cats were received 0.5 mg/kg of HDM7006 once weekly for five consecutive doses. Plasma samples were collected before and after drug administration to determine PK parameters and evaluate immunogenicity. Results: No gender differences were observed in system exposure of HDM7006 after IV or SC injection. HDM7006 exhibited a low clearance, a low apparent volume of distribution, and a half-life of 43.7 h in cats after IV injection. Following single SC injection, the median T Conclusions and clinical importance: HDM7006 exhibits predictable, dose-proportional PK and low immunogenicity, supporting a QW SC regimen in cats, and may offer a long-acting therapeutic option for feline weight management and metabolic regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.